Eric Shaff, Seres CEO
July 1, 2021 07:45 AM EDTUpdated 09:50 AM
Deals

Nestlé is bet­ting $525M on a bid to pi­o­neer world's first mi­cro­bio­me drug

Nicole DeFeudis

Editor

Af­ter fight­ing a years-long up­hill bat­tle with its oral mi­cro­bio­me can­di­date SER-109, Seres Ther­a­peu­tics fi­nal­ly got the Phase III re­sults it was look­ing for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times